Study S000662

Study to Evaluate the Effect of LY2189265 on Sitagliptin Pharmacokinetics in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01408888
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 29
Start: 2011-08
Primary completion: 2012-04
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: BIOLOGICAL:LY2189265; DRUG:Sitagliptin
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBDW

Registered primary outcomes

Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin [Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2]
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin [Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.